ArticleAnnals of internal medicine2022

First-Line Therapy for Type 2 Diabetes With Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists : A Cost-Effectiveness Study.

Jin G Choi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.